Morbidity

Percent prevalence of chronic conditions among users of chronic drugs program, 2016*

Chronic conditions	Prevalence
Cardiovascular diseases, atherosclerosis, coagulation problems and hypertension	47%
Diabetes	15%
Ulcers	10%
High cholesterol level	10%
Other diseases (Rheumatism, uric acid, glaucoma, osteoporosis...)	8%
Diseases of the nervous system	3%
Epilepsy	3%
Thyroid Problems	2%
Asthma	2%

*For previous years check the Statistical Bulletins' page

Newly reported HIV cases, 2020

Newly reported HIV cases,2021

Newly reported HIV cases, 2022

New reported HIV cases,2023

New reported HIV cases,2024

https://www.moph.gov.lb/userfiles/files/Prevention/TB%20Program/NTP-NAP%20Annual%20Report-2024.pdf

Number of Measles cases

	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Measles	9	1,760	235	39	44	126	952	1070	-	28	95	351

Source :MoPH 01/09/2024

Number of Tuberculosis cases*

Tuberculosis cases	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total number of cases	630	689	682	666	657	632	668	760	656	466	510	510	540
Number of Lebanese cases	330	341	337	312	305	271	254	288	277	233	263	249	225
Number of Non-Lebanese cases	300	348	345	354	352	361	414	472	379	233	247	261	315

*MOPH National Tuberculosis Program 01/05/2025

The trend in Tuberculosis cases by Nationality between 2019 and 2024

...

All

ATC	Name	B/G	Ingredients	Dosage	Form	Price
C10AB05	LIPANTHYL	B	Fenofibrate - 160mg	160mg	Tablet, film coated, modified release	1,154,238 L.L
C10AB05	LIPAFIB	G	Fenofibrate - 160mg	160mg	Tablet	627,127 L.L
J01DD04	LEBACEF	G	Ceftriaxone (sodium) - 1g	1g	Injectable powder for solution+diluent	643,765 L.L
J01DD04	LEBACEF	G	Ceftriaxone (sodium) - 1g, Lidocaine (ampoule) -	1g	Injectable powder for solution+diluent	568,253 L.L
J01DD04	LEBACEF	G	Ceftriaxone (sodium) - 1g	1g	Injectable powder for solution	5,793,881 L.L
J01DD04	LEBACEF	G	Ceftriaxone (sodium) - 1g	1g	Injectable powder for solution+diluent	508,100 L.L
J01DD04	LEBACEF	G	Ceftriaxone - 1g	1g	Injectable sterile powder for solution + lidocaine solvent	508,100 L.L
J01DD04	LEBACEF	G	Ceftriaxone - 1g	1g	Injectable sterile powder for solution + lidocaine solvent	508,100 L.L
J01DD04	LEBACEF	G	Ceftriaxone (sodium) - 1g	1g	Injectable powder for solution+diluent	508,100 L.L
J01DD04	LEBACEF	G	Ceftriaxone (sodium) - 1g	1g	Injectable powder for solution	5,793,881 L.L
J01DD04	LEBACEF	G	Ceftriaxone (sodium) - 1g	1g	Injectable powder for solution+diluent	643,765 L.L
J01DD04	LEBACEF	G	Ceftriaxone (sodium) - 1g, Lidocaine (ampoule) -	1g	Injectable powder for solution+diluent	568,253 L.L
J01DD04	LEBACEF	G	Ceftriaxone (sodium) - 1g	1g	Injectable powder for solution	5,793,881 L.L
N05BA06	LORAZEPAM	G	Lorazepam - 1mg	1mg	Tablet, scored	325,082 L.L
N01BB02	LIDOCAINE- ORBUCELL	G	Lidocaine HCl - 2%	2%	Injectable solution	1,787,950 L.L
N01BB02	LIDOCAINE PANPHARMA 2%	G	Lidocaine (HCl) - 20mg/ml	2%	Injectable solution	3,398,578 L.L
N01BB02	LIDO-CARE	G	Lidocaine - 2%	2%	Injectable solution	100,788 L.L
D01AC12	LOMEXIN	B	Fenticonazole nitrate - 2g/100g	2%	Cream	758,029 L.L
B01AB05	LOVENOX	BioTech	Enoxaparin sodium - 2,000UI (20mg)/0.2ml	2,000UI (20mg)/0.2ml	Injectable solution	467,657 L.L
L02BG04	LEFFTARA	G	Letrozole - 2.5mg	2.5mg	Tablet, film coated	2,060,111 L.L
L02BG04	LETROZOLE ARROW	G	Letrozole - 2.5mg	2.5mg	Tablet, film coated	2,402,790 L.L
L02BG04	LETROZOLE ARROW LAB	G	Letrozole - 2.5mg	2.5mg	Tablet, coated	2,000,981 L.L
L02BG04	LETROZOLE BIOGARAN	G	Letrozole - 2.5mg	2.5mg	Tablet, coated	2,402,790 L.L
L02BG04	LETROZOLE NEAPOLIS	G	Letrozole - 2.5mg	2.5mg	Tablet, film coated	2,060,111 L.L
G03CX01	LIVIAL	B	Tibolone - 2.5mg	2.5mg	Tablet	1,135,547 L.L
R06AX29	LABIXTEN	B	Bilastine - 2.5mg/ml	2.5mg/ml	Solution	463,626 L.L
N03AX18	LACOSAMIDE/GENEPHARM	G	Lacosamide - 200mg	200mg	Tablet	8,284,105 L.L
C10AB05	LIPANTHYL 200 M	B	Fenofibrate - 200mg	200mg	Capsule	1,115,364 L.L
G01AF12	LOMEXIN	B	Fenticonazole nitrate - 200mg	200mg	Ovule	810,359 L.L
J01MA02	LADININ	G	Ciprofloxacine (lactate) - 200mg/100ml	200mg/100ml	Injectable solution	892,591 L.L

...